Temozolomide

تموزولوماید

⚠ Unverified

🎗️ Antineoplastic And Immunomodulating AgentsOral alkylating agent

Market / country: 🇺🇸 USA

Temodar (US)

🧮 Dose calculator

Glioblastoma and anaplastic astrocytoma · Regimen source: FDA Temodar · 2.2

  • • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Temodar · 2.2
  • • Pneumocystis prophylaxis during the concomitant phase. Start only with ANC ≥1.5 × 10⁹/L and platelets ≥100 × 10⁹/L. FDA Temodar · 2.2FDA Temodar · 2.1

Enter age and weight.

🛡️ Safety & information

Contraindications

  • ⛔ History of serious hypersensitivity to temozolomide or dacarbazine. FDA Temodar · 4

Warnings

  • • Myelosuppression; hepatotoxicity; Pneumocystis pneumonia; secondary malignancies; embryo-fetal toxicity; do not open capsules. FDA Temodar · 5

Formulations

👥 Special populations

  • 🤰 PregnancyDangerous / avoid

    Label: can cause fetal harm. Dangerous in pregnancy. FDA Temodar · 8.1

    “Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , TEMODAR can cause fetal harm when administered to a pregnant woman.”
  • 🤱 BreastfeedingDangerous / avoid

    Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Temodar · 8.2

    “Because of the potential for serious adverse reactions, including myelosuppression from temozolomide in the breastfed children, advise women not to breastfeed during treatment with TEMODAR and for 1 week after the last dose.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Temodar · 8.4

    “Safety and effectiveness of TEMODAR have not been established in pediatric patients.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Temodar · 8.5

    “… ade 4 thrombocytopenia (20%) in the first cycle of therapy than patients less than 70 years of age [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) ] .”
  • ⚥ Females & males of reproductive potentialUse with caution

    Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Temodar · 8.3

    “Contraception Females Advise females of reproductive potential to use effective contraception during treatment with TEMODAR and for 6 months after the last dose.”

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Same class

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav